A Phase 2 interventional study of filgotinib in Psoriatic Arthritis, sponsored by Galapagos NV. Terminated at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-21.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Arthritis, Psoriatic with a site in Ukraine — none open to participants now, 6 under way, 2 of them phase 3. Arthritis, Psoriatic · Ukraine.
Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2017, is one of 6 in phase 2, and was the 12th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →None of the 22 studies in Arthritis, Psoriatic with a site in Ukraine is open now. The open studies under Arthritis, Psoriatic, anywhere →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 12 · Phase 4 2
First in 2007; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is below the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 389 across the 20 interventional studies, 11,000 across the 2 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 3 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Psoriatic with a site in Ukraine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486960Merck Sharp & Dohme LLCStudy to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | 2027-02-17 |
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active PsA. It is estimated that approximately 105 subjects will be rolled-over after they have completed the 16 weeks of double-blind treatment in core study GLPG0634-CL-224. Subjects will be administered filgotinib in this study until filgotinib is registered for PsA or until Week 304, whichever occurs first. The LTE study is concluded with a follow-up visit approximately 4 weeks after the last intake of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: filgotinib
one filgotinib oral tablet once daily.
Change in the proportion of subjects with adverse events
To asses safety and tolerability of filgotinib.
Time frame: Between entry visit and 4 weeks after the last dose.
Proportion of subjects achieving minimal disease activity (MDA)
To assess the effect of filgotinib on MDA in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects achieving American College of Rheumatology 20 (ACR20) response
To assess the effect of filgotinib on PsA as assessed by ACR20 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects achieving ACR50 response
To assess the effect of filgotinib on PsA as assessed by ACR50 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects achieving ACR70 response
To assess the effect of filgotinib on PsA as assessed by ACR70 in PsA patients
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with Psoriatic Arthritis Disease Activity Score (PASDAS) low disease activity (LDA, i.e. PASDAS ≤ 3.2)
To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with PASDAS Very Low Disease Activity (VLDA) (i.e. PASDAS ≤1.9)
To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Percentage of patients subjects with PASDAS LDA (i.e. PASDAS ≤3.2)
To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Percentage of patients subjects with PASDAS VLDA (i.e. PASDAS ≤1.9)
To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)
To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with DAPSA remission/LDA (DAPSA ≤14)
To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with DAPSA remission (DAPSA ≤4)
To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Psoriasis Area and Severity Index (PASI)
To assess the effect of filgotinib on PASI in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with PASI50
To assess the effect of filgotinib on PASI50 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with PASI75
To assess the effect of filgotinib on PASI75 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with PASI90
To assess the effect of filgotinib on PASI90 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects with PASI100
To assess the effect of filgotinib on PASI100 in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Physician's global assessment of psoriasis
To assess the affect of filgotinib on Physician's global assessment of psoriasis in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Patient's Global Assessment of psoriasis
To assess the affect of filgotinib on patient's global assessment of psoriasis in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in modified Nail Psoriasis Area and Severity Index (mNAPSI)
To assess the effect of filgotinib on mNAPSI in PsA patients assessment of psoriasis in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in pruritis numeric rating scale (NRS)
To assess the effect of filgotinib on NRS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Proportion of subjects achieving a pruritis numeric rating scale (NRS) response(improvement in pruritus NRS score of ≥3)
To assess the effect of filgotinib on NRS in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index
To assess the effect of filgotinib on SPARCC enthesitis index in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Leeds Dactylitis Index (LDI)
To assess the effect of filgotinib on Dactilytis in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from core baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
To assess the effect of filgotinib on physical function in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Change from baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue scale)
To assess the effect of filgotinib on FACIT-Fatigue scale in PsA patients.
Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.
Change from core baseline in 36-item Short-Form Health Survey (SF-36)
To assess the effect of filgotinib on SF-36 in PsA patients
Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.
Change from core baseline in Psoriatic Arthritis Impact of Disease Questionnaire (PsAID).
To assess the effect of filgotinib on PsAID in PsA patients.
Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.
Change from core baseline in individual components of the ACR response of improvement in multiple disease assessment criteria
To assess the effect of filgotinib on signs and symptoms of peripheral arthritis and physical function in PsA patients.
Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2017 to primary completion in Jun 2021, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634